Cytokinetics Inc Shares Close the Week 22.9% Lower - Weekly Wrap
The company saw its shares close the week 22.9% lower than last week, with trading volume higher than its 30 day average.
Jan 09, 2022 by Kwhen Finance Editors
Cytokinetics Inc (CYTK) shares closed this week 22.9% lower than it did at the end of last week. The stock is currently down 22.9% year-to-date, up 63.3% over the past 12 months, and up 170.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%.
Trading Activity
- Shares traded as high as $46.95 and as low as $34.00 this week.
- Shares closed 26.6% below its 52-week high and 98.4% above its 52-week low.
- Trading volume this week was 16.1% higher than the 10-day average and 38.4% higher than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
Fundamentals & Catalysts
- Over the past 12 months the company generated $-102,232,000 in earnings before interest and taxes from $58 million in revenue. It currently holds $425 million in cash and $35 million in debt.
- Its forward price-to-earnings (P/E) ratio of -8.360425362273979 is higher than its current P/E ratio of -12.89, implying that analysts are expecting a decrease in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -1.06. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 8.51 which means it currently has $8.51 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 23.08. This means that the stock is trading at a premium of 23 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 26.75.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 21.82.
P/E
-12.89
EBITDA
$-102,232,000
P/Book
23.08
Mkt Cap
$2B
P/Sales
26.75
Revenue
$58M
EPS (TTM)
-3.11
PEG Ratio
-1.06
EV/Revenue
21.82
Total Cash
$425M
Debt/Equity
8.51
Forward P/E
-8.36
Current Debt
$35M
Gross Profit
$58M
Dividend Date
-
Earnings Date
2022-02-24
Profit Margin
-2.31
Revenue/Share
0.82
Total Revenue
$58M
Enterprise Val
$1B
Put/Call Ratio
1.20
Revenue/Employee
0.00
Market Comparative Performance
- The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis
- The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis
- The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Cytokinetics Inc | -9.4 | -22.9 | 63.3 | -27.5 | 96.1 |
| Dow Jones Industrial Average | -0.0 | -0.3 | 18.7 | -2.0 | 23.2 |
| S&P 500 Index | -0.4 | -1.9 | 24.6 | -2.5 | 28.8 |
| Health Care | -0.7 | -5.2 | 13.5 | -5.5 | 21.4 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 657.9%
- The company's stock price performance over the past 12 months beats the peer average by -283.4%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Cytokinetics Inc | CYTK | -12.9 | -22.9 | 63.3 | -27.5 | 96.1 |
| Peer Avg | N/A | 9.7 | -3.0 | -34.5 | -56.6 | 13.8 |
| AMGEN Inc. | AMGN | 22.8 | 1.0 | 0.1 | -16.7 | 12.5 |
| Ligand Pharmaceuticals, Inc. - Class B | LGND | 35.4 | -6.4 | 34.9 | -34.3 | 41.4 |
| Array Technologies Inc | ARRY | 0 | -10.0 | -71.6 | -73.6 | 9.4 |
| Trevena Inc | TRVN | 0 | 6.5 | -74.4 | -80.1 | 10.1 |
| ARCA biopharma Inc | ABIO | 0 | -5.1 | -51.1 | -62.9 | 1.5 |
| Acorda Therapeutics Inc | ACOR | -0.1 | -4.2 | -45.0 | -72.1 | 7.6 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: